Bär & Karrer advises Lonza on the CHF 4.2 billion sale of Lonza’s Specialty Ingredients business to Bain Capital and Cinven

Lonza entered into a definitive agreement with Bain Capital and Cinven to sell Lonza’s Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion. The divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry.

The advisor

Bär & Karrer has acted as lead counsel to Lonza on the complex carve-out as well as the subsequent sale of Lonza’s Specialty Ingredients business. The team includes Urs Kägi (pictured), Rolf Watter, Nadina Duss, Michael Bänziger and Matthias Tanner (all M&A/Corporate and Commercial), Susanne Schreiber (Tax), Lukas Roesler (Finance), Ruth Bloch-Riemer (Social Security), Laura Widmer (Employment), Corrado Rampini and Rocco Rigozzi (both Real Estate), Mani Reinert (Competition), Thomas Stoltz and Frédéric Mancosu (both Notarial Services) as well as Markus Wang (IP).

As previously reported by Legalcommunity.ch, Lenz & Staehelin advises Bain Capital Private Equity and Cinven on this transaction. The team includes partners Tino Gaberthüel (Corporate / M&A – pictured), Beat Kühni (Real Estate), Marcel Tranchet (Finance), Astrid Waser (Competition) and Pascal Hinny (Tax) as well as Eric MeierAlex WilleXavier Grivel and Lisa Moser (all Corporate and M&A), Tobias Weber (Real Estate), Roland FischerKevin MacCabe (both Finance), Anja Affolter Marino (Employment/Pension), Leo Rusterholz (IT, Data Protection, Transitional Services), Lukas Aebi (Tax) and David Hitz (IP).